Elvitegravir-Cobicistat-TAF-FTC in Renal Impairment

Study 112

National HIV Curriculum

Elvitegravir-Cobicistat-TAF-FTC in Renal Impairment
Study 112: Design

- **Background**: Open-label, single-arm, phase 3 trial evaluating switching to once-daily elvitegravir-cobicistat-tenofovir alafenamide-emtricitabine from baseline ART*
- **Inclusion Criteria** (n = 242)
  - HIV RNA < 50 copies/mL for ≥6 months
  - eGFR stable at 30-69 mL/min ≥3 months
  - CD4 ≥50 cells/mm3
  - No new AIDS conditions in past 30 days
  - No resistance to EVG, FTC, or TDF
- **Treatment Arms**
  - Switch to EVG-COBI-TAF-FTC



***Baseline ART**

NRTIs: Tenofovir DF 65%, Abacavir 22%, Other NRTI 7%, No NRTI 5%

Third Agent: PI 44%, NNRTI 42%, INSTI 24%, CCR5 Antagonist 3%

Source: Pozniak A, et al. J Acquir Immune Defic Syndr. 2016;71:530-7.

Elvitegravir-Cobicistat-TAF-FTC in Renal Impairment Study 112: Result

Week 48 Virologic Response



Source: Pozniak A, et al. J Acquir Immune Defic Syndr. 2016;71:530-7.

Elvitegravir-Cobicistat-TAF-FTC in Renal Impairment Study 112: Subgroup Analysis Result

Change in Estimated GFR* from Baseline to Weeks 24 and 48



*GFR estimated by Cockcroft Gault

Source: Pozniak A, et al. J Acquir Immune Defic Syndr. 2016;71:530-7.

Elvitegravir-Cobicistat-TAF-FTC in Renal Impairment
Study 112: Result

Week 48: Changes in General Proteinuria



Source: Pozniak A, et al. J Acquir Immune Defic Syndr. 2016;71:530-7.

Elvitegravir-Cobicistat-TAF-FTC in Renal Impairment
Study 112: Result

Week 48: Changes in Tubular Proteinuria



Source: Pozniak A, et al. J Acquir Immune Defic Syndr. 2016;71:530-7.

Elvitegravir-Cobicistat-TAF-FTC in Renal Impairment
Study 112: Result

Week 48: Changes in Bone Mineral Density (BMD)



Source: Pozniak A, et al. J Acquir Immune Defic Syndr. 2016;71:530-7.

Elvitegravir-Cobicistat-TAF-FTC in Renal Impairment Study 112: Result

Week 48: Changes in Spine and Hip Bone Mineral Density (BMD)



Source: Pozniak A, et al. J Acquir Immune Defic Syndr. 2016;71:530-7.

Elvitegravir-Cobicistat-TAF-FTC in Renal Impairment
Study 112: Conclusions

Interpretation: “Switch to E/C/F/TAF was associated with minimal change in GFR. Proteinuria, albuminuria and bone mineral density significantly improved. These data support the efficacy and safety of once daily E/C/F/TAF in HIV+ patients with mild or moderate renal impairment without dose adjustment.”

Source: Gallant J, et al. J Acquir Immune Defic Syndr. 2016;73:294-8.

Acknowledgments

The **National HIV Curriculum** is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $1,021,448 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

AETC AIDS Education & Training Center Program

National HIV Curriculum

IDEA INFECTIOUS DISEASES EDUCATION & ASSESSMENT